Featuring Raj Mehra, PhD, Dr. Tim Whitaker, MD, Dr. Dean Burnett, PhD.
A discussion of SLS-002 (intranasal racemic ketamine), Seelos Therapeutics’ registration directed study that is currently enrolling in a randomized, double-blind, placebo-controlled study. The purpose of the study is to evaluate the efficacy, safety, and tolerability of repeat doses of SLS-002 in addition to standard of care on the symptoms of MDD and suicidality in patients who are assessed to be at an imminent risk of suicide.
1:10 pm
Second Stage
Nov 5
Featuring Raj Mehra, PhD, Dr. Tim Whitaker, MD, Dr. Dean Burnett, PhD.
A discussion of SLS-002 (intranasal racemic ketamine), Seelos Therapeutics’ registration directed study that is currently enrolling in a randomized, double-blind, placebo-controlled study. The purpose of the study is to evaluate the efficacy, safety, and tolerability of repeat doses of SLS-002 in addition to standard of care on the symptoms of MDD and suicidality in patients who are assessed to be at an imminent risk of suicide.